| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO | Director
3 companies
Nadav Kidron is President and CEO at ORMP, with reported holdings spanning 3 companies. Nadav Kidron's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $17.2M at current prices.
Our model assigns Nadav Kidron a middling insider score of 67/100, based on 3 past trades. Over a 12-month horizon, all 3 of those trades were profitable, with an average 12-month return of +41.4%.
Nadav Kidron's largest disclosed position is in ORMP as President and CEO, worth about $17.1M. The ORMP filings lean toward selling, a net 89,739 shares.
Nadav Kidron has 34 Form 4 filings on record from February 2015 to September 2026, across 3 companies: President and CEO at Oramed Pharmaceuticals (ORMP), 2015–2026; Director at Nano Dimension (NNDM), 2026; Director at Lifeward (LFWD), 2026.
The 63 reported transactions were 20 stock awards, 16 open-market purchases, 8 option or other derivative awards and 7 dispositions back to the company, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 6 purchases worth about $276K and 2 sales worth about $4.4M.
The largest open-market purchase was 100,000 shares of ORMP at an average $2.01 on March 14, 2023, about $201K. Twelve months later ORMP was up 33%.
The largest open-market sale was 220,000 shares of ORMP at an average $20.11 on August 9, 2021, about $4.4M. Twelve months later ORMP was down 59%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2023 | ORMP Oramed Pharmaceuticals Inc. | President and CEO | Buy | 26,000 | $2.04 | $53,014.00 | +26.0% | +74.7% | +32.1% | |
| Mar 14, 2023 | ORMP Oramed Pharmaceuticals Inc. | President and CEO | Buy | 100,000 | $2.01 | $201,000.00 | New | +88.0% | +32.5% | |
| Aug 9, 2021 | ORMP Oramed Pharmaceuticals Inc. | President and CEO | Sell | 220,000 | $20.11 | $4,423,144.00 | -25.3% | +41.1% | -59.4% | |
| Jul 11, 2018 | ORMP Oramed Pharmaceuticals Inc. | President and CEO | Buy | 122 | $5.92 | $722.18 | - | - | - | |
| Jul 10, 2018 | ORMP Oramed Pharmaceuticals Inc. | President and CEO | Sell | 61 | $5.98 | $364.97 | - | - | - | |
| May 12, 2016 | ORMP Oramed Pharmaceuticals Inc. | President and CEO | Buy | 1,000 | $6.95 | $6,953.00 | +0.1% | - | - | |
| May 12, 2015 | ORMP Oramed Pharmaceuticals Inc. | President and CEO | Buy | 600 | $6.60 | $3,962.00 | - | - | - | |
| Mar 19, 2015 | ORMP Oramed Pharmaceuticals Inc. | President and CEO | Buy | 2,600 | $3.88 | $10,082.00 | +0.3% | - | - |